NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/12/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization244.71 mln
Float38.95 mln
Earnings Date07/30/2026
Piotroski F-Score
1
/ 9
Very weak
Beneish M-Score
-2.47
Borderline
Relative Strength
86
/ 100
Strongly outperforming
Debt / Equity
0.20
Very low leverage
ROE
-52.71
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Voyager Therapeutics is a biotechnology company founded in 2013 and based in Lexington, Massachusetts, focused on developing treatments for serious neurological conditions such as Alzheimer's disease, Huntington's disease, ALS, and frontotemporal dementia. The company is advancing a range of approaches, including gene therapies, antibody programs, and small molecule treatments, alongside its proprietary TRACER platform for discovering new gene delivery tools. Voyager works alongside major partners including AstraZeneca, Novartis, and Alexion to broaden its reach across central nervous system diseases.
